Oxford Biomedica Plc Stock Net Income
| OXBDF Stock | USD 2.72 0.10 3.82% |
Oxford Biomedica plc fundamentals help investors to digest information that contributes to Oxford Biomedica's financial success or failures. It also enables traders to predict the movement of Oxford Pink Sheet. The fundamental analysis module provides a way to measure Oxford Biomedica's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Oxford Biomedica pink sheet.
Oxford |
Oxford Biomedica plc Company Net Income Analysis
Oxford Biomedica's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Oxford Biomedica Net Income | 19.01 M |
Most of Oxford Biomedica's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Oxford Biomedica plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Oxford Biomedica plc reported net income of 19.01 M. This is 94.43% lower than that of the Healthcare sector and 72.86% lower than that of the Biotechnology industry. The net income for all United States stocks is 96.67% higher than that of the company.
Oxford Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Oxford Biomedica's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Oxford Biomedica could also be used in its relative valuation, which is a method of valuing Oxford Biomedica by comparing valuation metrics of similar companies.Oxford Biomedica is currently under evaluation in net income category among related companies.
Oxford Fundamentals
| Return On Equity | -0.14 | |||
| Return On Asset | -0.024 | |||
| Profit Margin | (0.20) % | |||
| Operating Margin | (0.10) % | |||
| Current Valuation | 436.12 M | |||
| Shares Outstanding | 96.27 M | |||
| Shares Owned By Insiders | 6.19 % | |||
| Shares Owned By Institutions | 62.89 % | |||
| Price To Earning | 17.67 X | |||
| Price To Book | 1.69 X | |||
| Price To Sales | 3.60 X | |||
| Revenue | 142.8 M | |||
| Gross Profit | 82.64 M | |||
| EBITDA | 33.22 M | |||
| Net Income | 19.01 M | |||
| Cash And Equivalents | 118.55 M | |||
| Cash Per Share | 1.23 X | |||
| Total Debt | 107.5 M | |||
| Debt To Equity | 0.41 % | |||
| Current Ratio | 1.83 X | |||
| Book Value Per Share | 2.31 X | |||
| Cash Flow From Operations | 25.45 M | |||
| Earnings Per Share | 0.24 X | |||
| Number Of Employees | 959 | |||
| Beta | 0.97 | |||
| Market Capitalization | 548.76 M | |||
| Total Asset | 237.23 M | |||
| Working Capital | 12.54 M | |||
| Current Asset | 25.71 M | |||
| Current Liabilities | 13.17 M | |||
| Z Score | 3.0 | |||
| Net Asset | 237.23 M |
About Oxford Biomedica Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Oxford Biomedica plc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oxford Biomedica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oxford Biomedica plc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oxford Biomedica plc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. Note that the Oxford Biomedica plc information on this page should be used as a complementary analysis to other Oxford Biomedica's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Complementary Tools for Oxford Pink Sheet analysis
When running Oxford Biomedica's price analysis, check to measure Oxford Biomedica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oxford Biomedica is operating at the current time. Most of Oxford Biomedica's value examination focuses on studying past and present price action to predict the probability of Oxford Biomedica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oxford Biomedica's price. Additionally, you may evaluate how the addition of Oxford Biomedica to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |